- ►diabetesjournals.org PA Hollander, P Levy, MS Fineman, DG Maggs … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Treatment with pramlintide 120 μg BID led to a sustained reduction
from baseline in HbA 1c (−0.68 and −0.62% at weeks 26 and 52, respectively),
which was significantly greater than that seen with placebo (P < 0.05). The ... Cited by 167 - Related articles - BL Direct - All 5 versions
- Free from Publisher F Whitehouse, DF Kruger, M Fineman, L … - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—Treatment with pramlintide led to a mean reduction in HbA 1c of 0.67%
from baseline to week 13 that was significantly (P < 0.0001) greater than the
placebo reduction (0.16%), and a significant placebo-corrected treatment ... Cited by 135 - Related articles - BL Direct - All 6 versions
RE Ratner, R Dickey, M Fineman, DG Maggs, … - Diabetic Medicine, 2004 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 110 - Related articles - BL Direct - All 5 versions
M Fineman, C Weyer, DG Maggs, S Strobel, … - Hormone and metabolic research, 2002 - thieme-connect.com Aims: Amylin is a second beta-cell hormone that is normally co-secreted with
insulin in response to meals; it complements the effects of insulin in
postprandial glucose control, in part by suppressing glucagon secretion. In ... Cited by 92 - Related articles - BL Direct - All 10 versions
I Chapman, B Parker, S Doran, C Feinle- … - Diabetologia, 2005 - Springer Page 1. Diabetologia (2005) 48: 838–848 DOI 10.1007/s00125-005-1732-4 ARTICLE I.
Chapman . B. Parker . S. Doran . C. Feinle-Bisset . J. Wishart . S. Strobel . ... Cited by 85 - Related articles - All 5 versions
- ►diabetesjournals.org C Levetan, LL Want, C Weyer, SA Strobel, J … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In this study, 18 patients (16 of whom could be
evaluated) with type 1 diabetes (age 44 ± 11 years, HbA 1c 8.2 ± 1.3% [mean ±
SD]) were given mealtime injections of 30 μg pramlintide tid for 4 weeks ... Cited by 68 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org C Weyer, A Gottlieb, DD Kim, K Lutz, S … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In this randomized, single-blind,
placebo-controlled, five-way crossover study, 19 subjects with type 1 diabetes
using regular insulin and 21 subjects with type 1 diabetes using insulin ... Cited by 58 - Related articles - BL Direct - All 7 versions
DG Maggs, M Fineman, J Kornstein, T Burrell … - Diabetes/Metabolism Reviews - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 48 - Related articles - BL Direct - All 3 versions
P Hollander, DG Maggs, JA Ruggles, M … - Obesity research, 2004 - ncbi.nlm.nih.gov OBJECTIVE: Several randomized, placebo-controlled, double-blind trials in
insulin-treated patients with type 2 diabetes have shown that adjunctive therapy
with pramlintide reduces hemoglobin (Hb)A1c with concomitant weight loss. ... Cited by 83 - Related articles - BL Direct - All 2 versions
